Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine*

W LONDON,† V LONDON, C RUTHE, AND P WEIZERT

From the Medizinische Klinik Innenstadt, University of Munich, Munich, W Germany

SUMMARY In a double-blind, placebo controlled and randomised secretory study the effectiveness of pirenzepine, ranitidine, and their combination was compared intraindividually in eight healthy subjects receiving intravenous bolus injections. Pirenzepine (0·15 mg/kg) plus ranitidine (0·6 mg/kg) suppressed peptone-stimulated gastric acid secretion from 69±11 to 2±0·4 mmol H⁺/3 h; the mean percentage inhibition was 97%. Postprandial gastrin was unaffected. There were only minor side-effects in a few experiments (reduction of salivation, brief blurring of vision), but no prolactin stimulation after ranitidine or ranitidine plus pirenzepine. The combined application of ranitidine and pirenzepine inhibited meal-stimulated acid secretion more effectively and produced fewer side-effects than the combination of cimetidine plus pirenzepine studied previously.

The combined application of classical anticholinergics and H₂-receptor antagonists inhibits basal and stimulated gastric acid secretion in man more than either drug alone.1-4 In double-blind, placebo controlled and randomised investigations we have demonstrated5-9 that combined intravenous bolus injections of the antimuscarinic drug pirenzepine with cimetidine suppressed peptone-stimulated acid output more effectively (on average by 90%) than either drug alone. We concluded from our data that the 'optimal effective dose'10 of such an intravenous combination in man is 0·15 mg/kg pirenzepine plus 1·5 mg/kg cimetidine, producing a mean percentage inhibition of 80% of peptone-stimulated acid secretion and a clear reduction of acute side-effects of both drugs. As the side-effects of cimetidine given as intravenous bolus (endogenous prolactin stimulation) could not be eliminated completely, additional experiments with the new competitive H₂-blocker ranitidine seemed to be justified. We therefore studied the effects of the combination of pirenzepine plus ranitidine on peptone-stimulated gastric acid secretion, serum gastrin, serum prolactin, and side-effects, monitored or specified by the subjects.

Methods

Each subject had four tests which had to be carried out within a fortnight; the interval between two tests was at least three days. On separate days each subject received pirenzepine, ranitidine, pirenzepine plus ranitidine, and placebo in random order by slow intravenous bolus on a double-blind basis according to a predetermined randomisation code. Injections were given by a physician not otherwise involved in the study. Eight healthy volunteers (four female, four male) with a mean age of 28 years (range 22–37 years), a mean body weight of 67 kg (range 56–84 kg), and a mean height of 177 cm (range 160–195 cm) were studied. They had no history of upper abdominal disease, were not pregnant or breast-feeding, were not taking any concurrent medication, and had no persistent abnormality of haematology (haemoglobin concentration, haematocrit, white cell and platelet count, erythrocyte sedimentation rate), biochemistry (total bilirubin, transaminases, total protein and electrophoresis, prothrombin index, cholesterol, electrolytes, creatinine, urea-nitrogen, uric acid) or urine analysis screen (protein, sugar, urobilinogen, sediment).

The volunteers received 0·15 mg/kg pirenzepine and 0·6 mg/kg ranitidine intravenously given alone or in combination. The ranitidine dose was chosen according to Hagenmüller et al.11 who demonstrated that 40 mg ranitidine were equipotent to 200 mg...
Acid after pirenzepine and ranitidine

cimetidine intravenously. Bolus injections of isotonic saline were used as placebo. The study was approved by the Ethical Committee of the Medical Faculty of the University of Munich. All volunteers gave written consent to participate in this study after full explanation by the investigator.

Peptone-stimulated gastric acid secretion of the volunteers who had fasted overnight was measured by an in vivo intragastric titration method according to Fordtran and Walsh modified by Becker using an automatic combititrator (Deutsche Metrohm GmbH & Co., Filderstadt, FRG) for titration with 1 N sodium hydroxide with the end point of pH 5.5. The intragastric stimulus was a 10% aqueous solution of Bactopeptone (Difco Laboratories, Detroit/Michigan, USA) which was adjusted to pH 5.5 before intragastric instillation and circulation through the stomach via a double-luminal gastric tube (Levine-type Ch 16) by a peristaltic pump (Blutpumpe BP 742 from Fresenius Apparatebau, Bad Homburg, FRG) with an average speed of 280 ml/min. Continuous titration with monitoring of sodium hydroxide consumption at five minute intervals was carried out in all subjects lying in a left-lateral position and spitting out their saliva during the whole secretory study. Acid outputs were expressed as mmol H⁺ per 15 minutes and calculated as mmol H⁺ per three hours. At the beginning of each secretory study 300 ml of peptone solution were instilled via tube into the stomach. Losses of peptone solution via the pylorus were corrected during the test procedure. At the end of each test gastric volumes were aspirated completely.

Before the start of each study an intravenous cannula was inserted into a forearm vein and isotonic saline infused at 60 ml/h to keep the line patent. Fasting blood samples were taken at 0 and 15 minutes, after swallowing the tube at 30 minutes (before the start of intragastric titration of peptone-stimulated acid output), and then every 15 minutes during the test procedure. The intravenous bolus was injected via the cannula at 70 minutes—that is, 40 minutes after the start of intragastric titration when acid output had nearly reached a sustained plateau. The blood samples were cooled on ice before centrifugation. All the deep-frozen sera from the four different secretory studies of one volunteer were thawed at the same time and analysed in the same assay. Serum gastrin was estimated by our radioimmunoassay using the specific rabbit antibody 4562 which detects component I, big (G 34), little (G 17), and mini gastrin (G 14) in nearly equimolar potencyusing synthetic human gastrin I (MRC) as standard and a double-antibody as technique for separation of bound and free. The lower limit of detection is less than 2 pg/ml. Radioimmunological measurements of serum prolactin were performed using a specific antibody against human serum prolactin. This assay has a lower detection limit of less than 20 μU/ml. The quality control of both assays equal those of international standards.

Side-effects were monitored by the subjects during and after the secretory studies and also by careful observation of the volunteers during the test by the investigator. Peripheral pulse rate was counted at five minutes before and at two, seven, 15, 60, 120, and 180 minutes after the intravenous bolus. Only after the secretory studies were completed in all volunteers, was the randomisation code broken and the data evaluated. Statistical analysis was done using Wilcoxon matched pairs signed rank test. Only p values less than 0.01 were considered to be significant (two-tail reading).

Results

Acid secretion showed an excellent reproducibility during the stimulatory phase from 30 to 70 minutes before single or combined application of the drugs at 70 minutes (Fig. 1). The pronounced inhibitory effects of both drugs or their combination occurred within 20 minutes after the bolus injection. Pirenzepine had the weakest effect, and this seemed to be relatively stable throughout the test period. Compared with placebo its inhibition was significant within 35 minutes after drug injection and lasted from 105 to 240 minutes. The inhibitory effect of ranitidine was stronger, being significant within 20 minutes after intravenous bolus, and lasted from 90 to 255 minutes, although its effect wore off during the course of the test. The effects of pirenzepine and ranitidine were therefore significantly different only from 105 to 135 minutes. The combination showed a more drastic reduction of stimulated acid output; within five minutes after the bolus injection significant differences from placebo were noted (75 to 255 minutes). The differences versus ranitidine were significant from 135 to 255 minutes, when a rather stable and practically complete inhibition of peptone-stimulated acid secretion to mean values (±SEM) of 0-01±0-01 mmol H⁺/15 min (at 150 minutes) and 0-2±0-1 mmol H⁺/15 min (at 240 and 255 minutes) was established.

Fasting serum gastrin values were well reproducible at the beginning of the four tests (mean of all four tests at 30 minutes: 42 pg/ml). After intragastric instillation of peptone solution there was a significant increase to about 125 pg/ml (mean of all four tests at 45 minutes). During the secretory studies gastrin values remained raised and were not altered by the two drugs or their combination.

The histograms of calculated acid output per 3 hours (75 to 255 minutes of the test period) (Fig. 2) demonstrate the marked inhibitory effect of the com-
combined application of pirenzepine and ranitidine. Mean stimulated acid output per three hours (±SEM) was reduced from 68·8±11·0 mmol H\(^+\) (placebo) to 40·0±11·0 mmol H\(^+\) by 0·15 mg/kg pirenzepine, to 14·1±3·5 mmol H\(^+\) by 0·6 mg/kg ranitidine and to 1·9±0·4 mmol H\(^+\) by their combination. The mean percentage inhibition was 42% by pirenzepine, 80% by ranitidine, and 97% by pirenzepine plus ranitidine.

The serum concentrations of prolactin (Fig. 3) were drawn as median because of a rather great variance between individuals tested. All subjects had normal basal values which declined continually during the first 90 minutes of the investigations, but were not altered by injections, either by pirenzepine or ranitidine alone or by their combination.

Table 1 summarises the side-effects that were reported. Reduction of salivation occurred more often after the combination (five times) than after pirenzepine (three times) or ranitidine (once). Brief blurring of vision occurred only once after the combination. Two subjects complained of palpitations for a few minutes directly after the injection of pirenzepine and one after the combination, although there were no increases of peripheral pulse rates. Other unspecific side-effects were mild diarrhoea or loose stools in the afternoon of the test day or transient nausea and desire to urinate during the secretory studies. On average a total of 590 ml of 10% aqueous peptone solution was required during the secretory studies to maintain a constant speed of circulation for an exact titration of stimulated acid output. A mean
Acid after pirenzepine and ranitidine

Table 1  Side-effects volunteered by the subjects during and after the secretory studies

<table>
<thead>
<tr>
<th></th>
<th>Ranitidine 0-6 (mg/kg)</th>
<th>Pirenzepine 0-15 (mg/kg)</th>
<th>Ran. + Pir. 0-6+0-15 (mg/kg)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction of salivation</td>
<td>1/8</td>
<td>3/8</td>
<td>5/8</td>
<td>1/8</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>0/8</td>
<td>0/8</td>
<td>1/8</td>
<td>0/8</td>
</tr>
<tr>
<td>Palpitations</td>
<td>0/8</td>
<td>2/8</td>
<td>1/8</td>
<td>0/8</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1/8</td>
<td>3/8</td>
<td>1/8</td>
<td>0/8</td>
</tr>
<tr>
<td>Others: nausea, desire to urinate</td>
<td>2/8</td>
<td>1/8</td>
<td>2/8</td>
<td>1/8</td>
</tr>
</tbody>
</table>

of 460 ml of gastric volume was aspirated at the end of the tests. There was no correlation between the different drug injection and the consumption of peptone solution.

The mean peripheral arterial pulse rates counted before and at definite intervals after bolus injections are shown in Table 2. After ranitidine there were no significant alterations compared with placebo, whereas pulse rates increased ($p<0.05$) at two minutes after injection of pirenzepine. After pirenzepine alone and in combination the pulse rates decreased slightly at one, two, and three hours after the bolus injection. At two hours after the injection the difference between pulse rates after pirenzepine plus ranitidine and ranitidine alone was statistically significant ($p<0.01$).

**Discussion**

These experiments have shown that combined intravenous bolus injection of the antimuscarinic drug pirenzepine and the new $H_2$-receptor antagonist ranitidine inhibits food-stimulated gastric acid secretion in man by 97% and for more than three hours.
This complete inhibitory effect was even more pronounced than those achieved previously with combinations of pirenzepine (0.075 to 0.3 mg/kg) and cimetidine (1.5 to 3.0 mg/kg) which suppressed food-stimulated gastric acid secretion in healthy volunteers and patients with duodenal ulcer and gastric hypersecretion by 80 to 90%. Except in one study such marked reductions have not been established with combinations of H2-receptor antagonists (metiamide or cimetidine) and conventional anticholinergic drugs (poldine, propantheline, etc'). An explanation for this difference seems to be that pirenzepine is a more selective antimuscarinic drug on parietal cell function than conventional anticholinergic drugs, which have very similar binding affinities to muscarinic receptors in different organs and therefore produce a number of unpleasant side-effects, which set limits to their clinical use. By contrast, pirenzepine distinguishes between different subclasses of muscarinic receptors and has low-affinity binding in smooth muscle and heart, but high affinity sites in exocrine glands.18

It is not clear whether the drastic reduction of acid secretion by the combination of pirenzepine and ranitidine is of any clinical relevance. Ranitidine inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner—that is, high doses of ranitidine alone abolish stimulated acid output in man.19-21 Such complete inhibition cannot be achieved by increasing the cimetidine dose. It was shown that doubling the normal oral dose does increase cimetidine blood levels, but does not reduce food-stimulated or nocturnal acid secretion22 to a greater extent nor does it increase ulcer healing.24

The duration of action on peptone-stimulated acid output of 0.6 mg/kg ranitidine given as an intravenous bolus in this study is comparable with that of 3.0 mg/kg cimetidine in our previous investigations.9 and those of Sewing et al.23 However, the effect of 0.6 mg/kg ranitidine intravenously is more potent, resulting in a mean percentage inhibition of 80% compared with 60% by 3.0 mg/kg cimetidine intravenously—that is, ranitidine, in our model of meal-stimulated gastric acid secretion, is more than four to five times more potent on a molar basis than cimetidine.26

With present and previous acute experiments in man neither cimetidine,7 8 27 ranitidine,28 nor pirenzepine,7 29 30 either alone or in combination, significantly alter postprandial gastrin. From these investigations with specific receptor antagonists it might be concluded that neither H2- nor muscarinic receptors are important for food-stimulated gastrin release. Konturek et al.26 have recently pointed out differences between atropine and pirenzepine on sham-feeding induced gastrin responses as well.

Previous studies with increasing intravenous bolus injections in man showed that pirenzepine—in contrast with other tricyclic compounds9—had no stimulatory effects on serum prolactin.7 In our study bolus injections of ranitidine—in contrast with cimetidine7—had no prolactin stimulatory action. From experiments in rats it is known that cimetidine is an antiandrogen,31 whereas ranitidine is not.32 It is possible that high peaks of blood concentrations of cimetidine may relate to its antiandrogenic properties.31 33 34

Reduction of salivation, which occurred mainly after pirenzepine alone or in combination, and brief blurred vision were weak and tolerable side-effects. In previous investigations9 dryness of the mouth occurred as often after 3.0 mg/kg cimetidine as after 0.3 mg/kg pirenzepine—that is, ranitidine caused this symptom less frequently than cimetidine. Palpitations were noticed by a few volunteers, but these subjects did not have any alteration of peripheral pulse rate, and, in particular, no tachycardia. However, there had been a slight and short-lasting mean increase two minutes after intravenous bolus of pirenzepine alone and a decrease at one, two, and three hours after pirenzepine alone and in combination. At two hours after combination this decrease was significant (p<0.01). Ranitidine alone had no such effect on pulse rate, as already reported.21 The other side-effects cannot be attributed to the drugs administered. Mild diarrhoea or loose stools at the afternoon of the secretory study may occur as a consequence of losses of hypertonic peptone solution via the pylorus.

---

**Table 2** *Peripheral pulse rates in minutes (±SEM) before and after intravenous bolus injection*

<table>
<thead>
<tr>
<th></th>
<th>Before (min)</th>
<th>After intravenous bolus injection (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Placebo</td>
<td>68±2</td>
<td>66±2</td>
</tr>
<tr>
<td>Pirenzepine (0.15 mg/kg)</td>
<td>67±3</td>
<td>64±2</td>
</tr>
<tr>
<td>Ranitidine (0.6 mg/kg)</td>
<td>65±3</td>
<td>64±3</td>
</tr>
<tr>
<td>Pirenzepine + ranitidine (same doses)</td>
<td>64±5</td>
<td>64±2</td>
</tr>
</tbody>
</table>

*tp<0.05 versus placebo, ttp<0.05 versus ranitidine, ttp<0.01 versus ranitidine.
Acid after pirenzepine and ranitidine

(on average about 10% of all subjects investigated). Tolerable nausea is related to the gastric tube, and the desire to urinate could be due to the test lasting nearly five hours.

Significant decreases of heart rate have been reported after parenteral35 or high oral36 doses of pirenzepine. This effect contrasts with cardiac effects of conventional anticholinergics and is hard to interpret, as pirenzepine was shown to have low affinity sites in the heart.18 Nevertheless, there are experimental data that pirenzepine may act in part by sympathetic mechanisms.37 Recently, direct binding studies demonstrated muscarinic receptors in sympathetic ganglia which were characterised by high affinity pirenzepine binding.38

In our previous papers79 the possible clinical aspects of a combined application of cimetidine and pirenzepine were discussed in detail. Its clinical relevance is under trial in high-risk patients after bleeding from mucosal lesions stopped by laser-coagulation. As the combination of pirenzepine and ranitidine showed a stronger antisecretory effect and fewer side-effects, its clinical applicability should be studied, too. We agree with Langman et al.39: 'The choice between the drugs in treating duodenal ulcer is likely to be influenced by their proclivity to cause adverse effects rather than by their effect on healing'. In this respect it has to be pointed out that a complete inhibition of food-stimulated gastric acid secretion by combined application of muscarinic and H2-receptor antagonists might induce bacterial overgrowth of gastric flora and its potentially dangerous consequences.40 Therefore, such a combination should be applied only as short-term treatment in definable patients with complicated peptic ulcer disease.79

We are very grateful to Professor Dr J F Rehfeld, Aarhus/Denmark, and to Professor Dr K von Werder, Endocrinological Department of our clinic, for providing us with their excellent antibodies.

References


20Simon B, Kather H. Hemmung der Pentagastrin-


Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine.

W Londong, V Londong, C Ruthe and P Weizert

doi: 10.1136/gut.22.7.542

Updated information and services can be found at:
http://gut.bmj.com/content/22/7/542

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Gastrointestinal hormones (848)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/